JP2014505264A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505264A5
JP2014505264A5 JP2013553610A JP2013553610A JP2014505264A5 JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5 JP 2013553610 A JP2013553610 A JP 2013553610A JP 2013553610 A JP2013553610 A JP 2013553610A JP 2014505264 A5 JP2014505264 A5 JP 2014505264A5
Authority
JP
Japan
Prior art keywords
marker
level
determining
biological sample
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013553610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505264A (ja
JP5990542B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/024729 external-priority patent/WO2012109592A1/en
Publication of JP2014505264A publication Critical patent/JP2014505264A/ja
Publication of JP2014505264A5 publication Critical patent/JP2014505264A5/ja
Application granted granted Critical
Publication of JP5990542B2 publication Critical patent/JP5990542B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013553610A 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法 Expired - Fee Related JP5990542B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161441785P 2011-02-11 2011-02-11
US61/441,785 2011-02-11
US201161442454P 2011-02-14 2011-02-14
US61/442,454 2011-02-14
US201161472424P 2011-04-06 2011-04-06
US61/472,424 2011-04-06
PCT/US2012/024729 WO2012109592A1 (en) 2011-02-11 2012-02-10 Methods for diagnosing systemic lupus erythematosus

Publications (3)

Publication Number Publication Date
JP2014505264A JP2014505264A (ja) 2014-02-27
JP2014505264A5 true JP2014505264A5 (enExample) 2015-04-02
JP5990542B2 JP5990542B2 (ja) 2016-09-14

Family

ID=45774332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013553610A Expired - Fee Related JP5990542B2 (ja) 2011-02-11 2012-02-10 全身性エリテマトーデスのリスクスコアを算出する方法

Country Status (4)

Country Link
US (6) US10132813B2 (enExample)
EP (1) EP2673644B1 (enExample)
JP (1) JP5990542B2 (enExample)
WO (1) WO2012109592A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10132813B2 (en) * 2011-02-11 2018-11-20 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
BR112015018964B1 (pt) * 2013-02-08 2022-08-02 Allegheny-Singer Research Institute Método para determinar se um paciente se classifica como não apresentando ter lupus e sistema para executar o método para determinar se um paciente se classifica como não apresentando ter lupus
US9863946B2 (en) 2013-02-08 2018-01-09 Allegheny-Singer Research Institute Cell-bound complement activation products as diagnostic biomarkers for pre-lupus
CN105229470B (zh) * 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
EP3117215B1 (en) * 2014-03-13 2019-05-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnosis method for lupus
BR112017002575B1 (pt) * 2014-08-08 2023-11-07 Allegheny Singer Research Institute Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo
JP6840391B2 (ja) 2015-06-19 2021-03-10 セラ プログノスティックス， インコーポレイテッド 早産を予測するためのバイオマーカーの対
WO2017023781A1 (en) * 2015-07-31 2017-02-09 Allegheny-Singer Research Institute Cell-bound complement activation product assays as companion diagnostics for antibody-based drugs
CA3170448A1 (en) * 2020-09-28 2022-03-31 Joseph M. Ahearn Methods for determining a level of a cell fragment-bound complement activation product
KR102608933B1 (ko) * 2021-10-20 2023-12-01 재단법인 아산사회복지재단 전신 홍반성 루푸스 환자의 루푸스 신염 진단용 바이오마커 조성물 및 이를 이용한 루푸스 신염 진단에 필요한 정보를 제공하는 방법
CN119889651B (zh) * 2024-12-24 2025-11-18 北京医院 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256708B2 (en) 1999-06-23 2007-08-14 Visicu, Inc. Telecommunications network for remote patient monitoring
EP1432731B1 (en) 2001-09-10 2010-09-01 University Of Pittsburgh Of The Commonwealth System Of Higher Education Diagnosis and monitoring of systemic lupus erythematosus and of scleroderma
US7588905B2 (en) 2003-04-16 2009-09-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification and monitoring of systemic lupus erythematosus
US8080382B2 (en) 2003-06-13 2011-12-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monitoring immunologic, hematologic and inflammatory diseases
WO2005108988A2 (en) 2004-04-09 2005-11-17 University Of Pittsburgh Real time method of detecting acute inflammatory conditions
DK1745287T3 (da) * 2004-05-11 2011-01-24 Univ Pittsburgh Diagnostisering og monitorering af inflammatoriske sygdomme ved at måle komplementkomponenter på hvide blodlegemer
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
EP2008213A1 (en) * 2006-04-07 2008-12-31 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Systems and methods for predicting an individual's risk of developing rheumatoid arthritus
CA2738952A1 (en) * 2008-10-16 2010-04-22 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
WO2011047337A2 (en) * 2009-10-16 2011-04-21 Exagen Diagnostics, Inc. Cell-based complement activation product algorithm for diagnosing systemic lupus erythematosus
EP2336769A1 (en) 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Trigger assay for differentiating between rheumatic and non-rheumatic disorders
EP2362222B1 (en) 2010-02-22 2013-06-26 Medipan GmbH Method and device for the simultaneous detection of antibodies bound to synthetic and cellular and/or tissue substrates
US10132813B2 (en) 2011-02-11 2018-11-20 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
EP2823311B1 (en) 2012-03-06 2016-04-27 Life Technologies Corporation Biomarkers for systemic lupus erythematosus
CN105229470B (zh) 2013-03-15 2018-11-27 艾克斯肯诊断股份有限公司 用于治疗和诊断系统性红斑狼疮的方法

Similar Documents

Publication Publication Date Title
JP2014505264A5 (enExample)
Salumets et al. Epigenetic quantification of immunosenescent CD8+ TEMRA cells in human blood
US20200011866A1 (en) Biodosimetry panels and methods
Gökmen et al. Neutrophil–lymphocyte ratio connected to treatment options and inflammation markers of ankylosing spondylitis
Jansen et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities
Didier et al. Immune correlates of aging in outdoor-housed captive rhesus macaques (Macaca mulatta)
Rahman et al. Development and validation of an early scoring system for prediction of disease severity in COVID-19 using complete blood count parameters
Paczesny Post‐haematopoietic cell transplantation outcomes: why ST2 became a ‘golden nugget’biomarker
Benson et al. A network-based analysis of allergen-challenged CD4+ T cells from patients with allergic rhinitis
CN119534864B (zh) 一种新型的IgG4相关性疾病的标志物及其应用
JP2017528734A5 (enExample)
Zingaropoli et al. JC Virus‐DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus
CN119889651B (zh) 一种基于流式细胞术的系统性红斑狼疮评估模型的构建方法及系统性红斑狼疮评估方法
Manolis et al. The European Medicines Agency experience with biomarker qualification
Barnes et al. Use of blood based biomarkers in the evaluation of Crohn’s disease and ulcerative colitis
Punukollu et al. Genomic and Biomarker Innovations in Predicting Kidney Transplant Rejection
RU2017107273A (ru) Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров
Quismorio Jr et al. Clinical application of serologic tests, serum protein abnormalities, and other clinical laboratory tests in systemic lupus erythematosus
Florez et al. Progress and challenges in diagnosis and treatment of rejection following liver transplantation
Ye et al. Adenosine deaminase as a potential diagnostic and prognostic biomarker for severe fever with thrombocytopenia syndrome
Wicks et al. T lymphocyte phenotype of contact‐allergic patients: experience with nickel and p‐phenylenediamine
Boin et al. Evaluation of topoisomerase‐1‐specific CD8+ T‐cell response in systemic sclerosis
Deane Learning about the natural history of rheumatoid arthritis development through prospective study of subjects at high risk of rheumatoid arthritis–related autoimmunity
Ahearn et al. The lupus biomarker odyssey: one experience
RU2015138144A (ru) Клеточно-связанные продукты активации комплемента в качестве диагностических биомаркеров волчанки в доклинической стадии